Opioid Use Disorder Market Size in the 7MM was ~USD 2000 Million in 2023, and it is expected to grow by 2034, according to DelveInsight

The Opioid Use Disorder Market was valued at ~USD 2000 Million in 2023 and is projected to grow at a robust CAGR during the study period (2020–2034). DelveInsight’s Comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Opioid Use Disorder Market Landscape. By analyzing historical data, current Opioid Use Disorder Market Dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Opioid Use Disorder Market is increasingly guided by biomarker-driven strategies. Opioid Use Disorder (OUD) is a chronic, relapsing medical condition characterized by the compulsive use of opioids despite harmful consequences. Opioids include prescription pain relievers such as morphine, oxycodone, and hydrocodone, as well as illicit substances like heroin and synthetic opioids such as fentanyl. OUD significantly affects physical health, mental well-being, social functioning, and overall quality of life, making it a major public health concern worldwide.

DelveInsight’s report, “Opioid Use Disorder Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Opioid Use Disorder Market landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. Additionally, it examines Opioid Use Disorder Market Dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Opioid Use Disorder Market Outlook, drug uptake, treatment scenario, and epidemiology trends, click here @ Opioid Use Disorder Market Forecast

Key Takeaways from Opioid Use Disorder Market Report

• As per DelveInsight’s estimates, the total Opioid Use Disorder prevalent population in the US was more than 2,100,000 in 2023.
• Opioid Use Disorder was more common in males compared to females across the 7MM.
• Most cases of Opioid Use Disorder are found in the age group of 18 to 25 years, followed by 26 or older years.
• The Opioid Use Disorder prevalent population in EU4 and the UK was ~1,440,000 cases in 2023 and the highest prevalent population was accounted by Germany.
• The leading Opioid Use Disorder Companies, such as Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Viatris Inc., Pfizer, Inc., Hikma Pharmaceuticals PLC, Camurus, and others.
• Promising Opioid Use Disorder Therapies such as CAM2038, BXCL501, MN-166, AZD4041, CVL-354, INDV-2000, NYX-783, and others

Opioid Use Disorder Overview

Opioid Use Disorder (OUD) is a chronic, relapsing medical condition characterized by the compulsive use of opioids despite harmful consequences. It affects brain function and behavior, leading to significant health, social, and economic challenges worldwide. Opioid Use Disorder develops from the repeated use of opioids such as prescription pain relievers (e.g., oxycodone, morphine), heroin, or synthetic opioids like fentanyl. Over time, these substances alter the brain’s reward system, creating physical dependence and intense cravings. Individuals with OUD may experience tolerance (needing higher doses for the same effect) and withdrawal symptoms when opioid use is reduced or stopped.

Get a Free sample for the Opioid Use Disorder Market Report @ https://www.delveinsight.com/report-store/opioid-use-disorder-market

Key Trends in Opioid Use Disorder Market

Growing Adoption of Medication-Assisted Treatment (MAT)

Medication-assisted treatment continues to dominate the OUD market due to its proven clinical effectiveness. Therapies combining pharmacological agents with behavioral and psychological support are increasingly preferred over abstinence-only approaches. The expanding acceptance of MAT across hospitals, outpatient clinics, and community-based treatment centers is strengthening market penetration and improving long-term recovery outcomes.

Shift toward Long-Acting and Extended-Release Therapies

A notable trend in the market is the increasing focus on long-acting and extended-release formulations. These therapies help reduce dosing frequency, improve patient adherence, and lower the risk of misuse or diversion. Such innovations are particularly valuable in addressing treatment continuity challenges and enhancing patient compliance in real-world settings.

Integration of Digital Health and Telemedicine Solutions

Digital health platforms and telemedicine are playing an increasingly important role in OUD management. Virtual consultations, digital behavioral therapy programs, and remote patient monitoring tools are expanding treatment access, especially in underserved and rural populations. These solutions also support continuous engagement and relapse prevention, contributing to improved treatment outcomes.

Rising Emphasis on Harm Reduction Strategies

Harm reduction initiatives are becoming an integral component of the OUD market. Increased availability of overdose-reversal agents, patient education programs, and safer prescribing practices are complementing treatment efforts. These strategies are helping reduce mortality rates and creating pathways for individuals to enter structured treatment programs.

Supportive Policy and Regulatory Environment

Government initiatives and policy reforms are positively influencing market growth. Expanded insurance coverage, relaxed prescribing regulations for OUD medications, and increased funding for addiction treatment infrastructure are improving access to evidence-based therapies. Such measures are also contributing to stigma reduction and higher treatment adoption rates.

Emergence of Personalized Treatment Approaches

Personalized and patient-centric treatment strategies are gaining traction in the OUD market. Factors such as patient history, behavioral patterns, and comorbidities are increasingly being considered when designing treatment plans. This approach aims to enhance therapeutic effectiveness and improve long-term recovery success.

Expanding Market Opportunities across Regions

While North America remains the largest market due to high disease prevalence and strong treatment infrastructure, other regions are experiencing growing awareness and improved access to care. Expanding healthcare investments and rising diagnosis rates in emerging markets are expected to create new growth opportunities over the forecast period.

Opioid Use Disorder Epidemiology Segmentation in the 7MM

The Opioid Use Disorder Market Report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into-

• Total Opioid Use Disorder Diagnosed prevalent cases
• Opioid Use Disorder Gender-specific cases
• Opioid Use Disorder Age-specific cases
• Opioid Use Disorder Severity-specific cases
• Total Opioid Use Disorder Treated cases

Download the report to understand which factors are driving Opioid Use Disorder Epidemiology trends @ Opioid Use Disorder Epidemiology Forecast

Recent Development in the Opioid Use Disorder Treatment Landscape

• In January 2026- New York State Psychiatric Institute conducted a study aims to evaluate the safety and efficacy of BXCL501 compared with lofexidine and placebo in individuals with opioid use disorder who are physically dependent on opioids. During a 7-day inpatient opioid withdrawal period, utilizing a methadone taper, participants will receive sublingual BXCL501, lofexidine, or placebo. Compared with lofexidine, dexmedetomidine is anticipated to demonstrate a superior safety profile, with fewer adverse effects on blood pressure and cardiac rhythm. The study will be conducted across three sites: NYSPI, Clinilabs, Inc., and Yale University.

Opioid Use Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential Opioid Use Disorder drugs recently launched in the Opioid Use Disorder market or expected to get launched during the study period. The analysis covers Opioid Use Disorder Market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Opioid Use Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Opioid Use Disorder Companies and Therapies

• CAM2038: Braeburn Pharmaceuticals
• BXCL501: BioXcel Therapeutics
• MN-166: MediciNova
• AZD4041: AstraZeneca
• CVL-354: Cerevel Therapeutics, LLC
• INDV-2000: Indivior Inc.
• NYX-783: Aptinyx

To know more about Opioid Use Disorder Companies working in the treatment market, visit @ Opioid Use Disorder Clinical Trials and Therapeutic Assessment

Opioid Use Disorder Market Drivers

• Rising Prevalence of Opioid Addiction

The global burden of opioid misuse and dependence continues to escalate, particularly in developed economies such as the United States, where both prescription and illicit opioid use have contributed to increased incidence and diagnosis of OUD. This sustained rise in opioid addiction cases is a primary driver of market demand for effective treatments and care pathways.

• Growing Adoption of Medication-Assisted Treatment (MAT)

Medication-assisted treatment combining FDA-approved pharmacotherapies (such as buprenorphine, methadone, and naltrexone) with behavioral interventions has become the gold standard in managing opioid dependence. The increasing acceptance of MAT among clinicians and healthcare systems is significantly expanding the addressable treatment market.

• Advances in Therapeutic Options

Ongoing R&D efforts are leading to novel and improved treatment modalities, including long-acting injectables, depot formulations, and abuse-deterrent technologies. These innovations aim to enhance treatment adherence, reduce relapse rates, and provide differentiated safety profiles, further driving clinical uptake and market growth.

• Increased Awareness and Diagnosis

Greater public and professional awareness of opioid addiction and its health consequences has led to more individuals seeking diagnosis and treatment. Educational efforts to reduce stigma and promote early intervention are broadening the patient population engaging with evidence-based care programs.

• Expansion of Treatment Infrastructure

Expansion of healthcare infrastructure, including rehabilitation centers, outpatient clinics, and telehealth platforms, is improving access to OUD care. Telemedicine, in particular, enables remote counseling and monitoring services, making treatment more accessible to underserved and rural populations

Opioid Use Disorder Market Barriers

• Persistent Social Stigma and Patient Reluctance

Stigma associated with opioid dependence and addiction remains one of the most formidable barriers facing the OUD market. Despite growing recognition of OUD as a chronic medical condition, misconceptions around addiction persist among patients, caregivers, and some healthcare providers. Social judgement and fear of discrimination deter individuals from seeking treatment, leading to underdiagnosis and suboptimal uptake of available therapies. In many regions, patients avoid disclosing their condition due to concerns about social exclusion or employment discrimination, further widening the treatment gap.

• Limited Treatment Access, Especially in Underserved Regions

Access to evidence-based treatment remains unevenly distributed. Rural communities and underserved regions grapple with a shortage of specialized addiction care providers, limited infrastructure, and transportation challenges. Even where effective Medication-Assisted Treatment (MAT) options exist, inadequate facility availability and trained personnel constrain patient access. This geographic disparity disproportionately affects low-income and remote populations, creating significant unmet need.

• Complex and Stringent Regulatory Environment

The regulatory framework governing OUD treatments is often fragmented and stringent. Regulatory authorities across different regions, such as the FDA and EMA, maintain varied requirements for drug approval and prescribing practices. Certain MAT medications, like methadone and buprenorphine, are subject to strict controls, including mandatory clinic attendance or special prescribing waivers, which restrict provider participation and limit patient access. These regulatory complexities increase development timelines and compliance costs for pharmaceutical companies, slowing the introduction and adoption of novel therapies.

• Economic and Reimbursement Barriers

High treatment costs and limited reimbursement coverage pose barriers for both patients and healthcare systems. Many OUD therapies, especially long-acting injectables or combination regimens, are expensive, and out-of-pocket costs can be prohibitive without adequate insurance coverage. Variability in reimbursement policies across payers and regions further complicates therapy accessibility and adoption. Insurance requirements such as prior authorizations introduce additional bureaucratic hurdles, delaying treatment initiation during critical windows.

• Treatment Adherence and Relapse Challenges

Long-term management of OUD is complex, with high relapse rates impacting treatment success and market growth. Patients may struggle with adherence due to side effects, psychosocial issues, or loss to follow-up. The chronic nature of opioid dependence necessitates sustained engagement with healthcare systems, but continuity of care is often disrupted by socioeconomic factors, limited support structures, or stigma within clinical settings.

• Limited Provider Knowledge and Training

Healthcare providers, particularly in general practice and primary care settings, may lack adequate training in addiction medicine. This knowledge gap reduces the number of clinicians willing or able to initiate and manage OUD therapies, especially MAT regimens, thereby limiting access for patients seeking help. Expanding training and educational programs is critical to enhancing provider confidence and capacity in delivering comprehensive OUD care.

Scope of the Opioid Use Disorder Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Opioid Use Disorder Companies- Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Viatris Inc., Pfizer, Inc., Hikma Pharmaceuticals PLC, Camurus, and others.
• Opioid Use Disorder Therapies- CAM2038, BXCL501, MN-166, AZD4041, CVL-354, INDV-2000, NYX-783, and others
• Opioid Use Disorder Therapeutic Assessment: Opioid Use Disorder current marketed and Opioid Use Disorder Emerging Therapies
• Opioid Use Disorder Market Dynamics: Opioid Use Disorder market drivers and Opioid Use Disorder Market Barriers
• Opioid Use Disorder Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Opioid Use Disorder Unmet Needs, KOL’s views, Analyst’s views, Opioid Use Disorder Market Access and Reimbursement

Discover more about therapies set to grab the major Opioid Use Disorder Market Share @ Opioid Use Disorder Treatment Market

Table of Contents

1. Key Insights

2. Opioid Use Disorder Market Report Introduction

3. Opioid Use Disorder Executive Summary

4. Opioid Use Disorder Key Events

5. Opioid Use Disorder Epidemiology and Market Forecast Methodology

6. Opioid Use Disorder Market Overview at a Glance

7. Opioid Use Disorder Disease Background and Overview

8. Opioid Use Disorder Epidemiology and Patient Population

9. Opioid Use Disorder Patient Journey

10. Opioid Use Disorder Marketed Drugs

11. Opioid Use Disorder Emerging Drugs

12. Opioid Use Disorder: 7MM Analysis

13. Opioid Use Disorder Unmet Needs

14. Opioid Use Disorder SWOT Analysis

15. Opioid Use Disorder KOL Views

16. Opioid Use Disorder Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.